Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives

Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives

Glioblastoma (GBM) is the most common malignant brain tumor. Despite multimodality treatment with surgical resection, radiation therapy, chemotherapy, and tumor treating fields, recurrence is universal, median observed survival is low at 8 months and 5-year overall survival is poor at 7%. Immunother...

Full description

Bibliographic Details
Main Authors: Ugur Sener, Michael W. Ruff, Jian L. Campian
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:International Journal of Molecular Sciences
Subjects:
glioblastoma
immunotherapy
checkpoint inhibitor
CAR T
vaccine therapy
viral therapy
Online Access:https://www.mdpi.com/1422-0067/23/13/7046

Internet

https://www.mdpi.com/1422-0067/23/13/7046

Similar Items